fbpx Skip to main content

BioCommunique Article

Adamas Pharmaceuticals, Inc. today announced it has signed an agreement to settle its ongoing patent litigation with Osmotica Pharmaceutical US LLC

Adamas Announces Global Rights to OSMOLEX ER

  • 2020-12-10T21:30:00.000+0000
  • California
  • Author: Pavel Svoboda

Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has signed an agreement to settle its ongoing patent litigation with Osmotica Pharmaceutical US LLC, a subsidiary of Osmotica Pharmaceuticals plc. As a result of this agreement, both parties will drop their respective claims relating to the patent litigation, and Adamas will acquire the global rights to OSMOLEX ER® for $7.5 million.

Adamas’ current portfolio consists of GOCOVRI® (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. OSMOLEX ER (amantadine) extended-release tablets is FDA-approved for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients.

As part of the acquisition, Adamas will receive existing inventory and all rights to OSMOLEX ER. Parties also entered a supply agreement in which Osmotica will be the sole manufacturer of OSMOLEX ER. Both parties are working together to ensure continuity of product supply to patients.

Read more about Adamas’ announcement here .